Systemic Inflammatory Response, Bacterial Translocation and Nitric Oxide Donors
Authors: Francisco S. Lozano Sanchez,; Rogelio Gonzalez-Sarmiento,
Source: Inflammation & Allergy - Drug Targets, Volume 6, Number 2, June 2007 , pp. 139-141(3)
Publisher: Bentham Science Publishers
Abstract:
Abdominal aortic surgery is relatively common and is associated with considerable post-operative morbidity and death. The aortic cross-clamping (supra or infrarenal) necessary for the insertion of a vascular graft, often in circumstances of haemorrhagic shock (e.e. a ruptured aneurysm) elicits a Systemic Inflammatory Response Syndrome (SIRS) and an Ischaemia-Reperfusion syndrome (I-R), with affectation of many organs including the kidneys and the intestine. Experimentally, the exogenous use of nitric oxide donors has proved to be able to control the SIRS, minimising the damage due to I-R and protecting from renal dysfunction and BT. However, clinical experience in these situations is still limited. Here we review the current status and experience of the authors in the use of nitric oxide donors in the control of the SIRS induced by infrarenal, suprarenal aortic cross-clamping, with or without haemorrhagic shock; and the Bacterial Translocation phenomenon (BT) induced by aortic cross-clamping below the mesenteric artery with or without associated hemorrhaging.Keywords: Systemic inflammatory response syndrome; bacterial translocation; nitric oxide donors
Document Type: Research article
DOI: http://dx.doi.org/10.2174/187152807780832283
Publication date: 2007-06-01
- Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
- In this: publication
- By this: publisher
- In this Subject: Allergy & Immunology , Pharmacology
- By this author: Francisco S. Lozano Sanchez, ; Rogelio Gonzalez-Sarmiento,

Shopping cart
Receive new issue alert
Get Permissions